In severe, uncontrolled asthma, tezepelumab reduced exacerbations over 1 y regardless of type 2 inflammation level.
other
Where this comes from
- Record sourced from PubMed, PMID 37931261.
- Also identified by DOI 10.7326/J23-0084.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Corren J, Menzies-Gow A, Chupp G, et al. <b>Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials.</b> Am J Respir Crit Care Med. 2023;208:13-24. 37015033.
Medical subject headings
- Asthma